A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
A phase 1/2 trial of Pembrolizumab, Lenvatinib, Sacituzumab tirumotecan and Dexamethasone in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) is a phase 1/2 interventional study registered as NCT05319730 by Merck Sharp & Dohme LLC, with 230 participants planned, started 2023-05-16 and due to reach its primary completion in 2027-06-11. Interventions recorded: Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib and Sacituzumab tirumotecan.
Similar pages
not linked directly; found by shared links- TrialPembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Shares Sacituzumab tirumotecan, Dexamethasone, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Pembrolizumab and the tag pipeline.
- TrialSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Pembrolizumab and the tag pipeline.